* Immunic Inc reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -51 cents. The mean expectation of six analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -23 cents to -19 cents per share.

* Reported revenue was zero​; analysts expected $7.50 thousand.

* Immunic Inc's reported EPS for the quarter was a loss of 24 cents​.

* The company reported a quarterly loss of $24.37 million.

* Immunic Inc shares had fallen by 28.5% this quarter and lost 21.3% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 5.3% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunic Inc is 10.25 This summary was machine generated from LSEG data November 7 at 02:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.22 -0.24 Missed

Jun. 30 2024 -0.21

Dec. 31 2023 -0.30

Dec. 31 2023 -0.51 -0.48 Beat